SCHEMBL5150103

SCHEMBL5150103

COC(=O)c1ccc(NCC2CCCN2C(=O)OC(C)(C)C)cc1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.52
FPR3 P25089 1/20 0.49
FPR2 P25090 1/20 0.49
DPP4 P27487 2/20 0.47
OPRD1 P41143 1/20 0.46
ALDH1A1 P00352 1/20 0.46
RAB9A P51151 1/20 0.46
UCHL1 P09936 1/20 0.45
USP30 Q70CQ3 1/20 0.45
KDM1A O60341 1/20 0.44
HDAC1 Q13547 1/20 0.43
HDAC6 Q9UBN7 1/20 0.43
KMT2A Q03164 3/20 0.42
MEN1 O00255 2/20 0.42
ABL1 P00519 1/20 0.41
RIN1 Q13671 1/20 0.41
PRMT5 O14744 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29939753 0.97 NPC1 (0.48) NPC1FPR3FPR2DPP4OPRD1
SCHEMBL5152852 0.90 NPC1 (0.53) NPC1FPR3FPR2OPRD1ALDH1A1
SCHEMBL12810104 0.86 FPR2 (0.62) NPC1FPR3FPR2DPP4OPRD1
SCHEMBL12311356 0.86 OPRD1 (0.53) NPC1FPR3FPR2DPP4OPRD1
SCHEMBL3042734 0.85 HDAC1 (0.46) NPC1FPR3FPR2DPP4OPRD1
SCHEMBL28581840 0.84 FPR3 (0.45) NPC1FPR3FPR2DPP4OPRD1
SCHEMBL28581838 0.84 FPR3 (0.45) NPC1FPR3FPR2DPP4OPRD1
SCHEMBL21834842 0.84 NPC1 (0.48) NPC1FPR3FPR2DPP4OPRD1
SCHEMBL4308226 0.83 PRMT5 (0.50) NPC1FPR3FPR2OPRD1ALDH1A1
SCHEMBL4308216 0.83 PRMT5 (0.50) NPC1FPR3FPR2OPRD1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070054909-A1 VLA-4 inhibitor compounds DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-03-08 US disclosed
US-7179819-B2 VLA-4 inhibitor compounds DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-02-20 US disclosed
US-20040229858-A1 VLA-4 inhibitor compounds DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-11-18 US disclosed
US-6756378-B2 BENZYL -UREA, -THIOUREA, OR -GUANIDINE DERIVATIVES THAT INHIBIT THE BINDING OF LIGANDS TO ALPHA 4 BETA 1 INTEGRIN (VLA-4) PHARMACOPEIA DRUG DISCOVERY, INC. 2004-06-29 US disclosed
US-20030078249-A1 VLA-4 inhibitor compounds DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2003-04-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030078249-A1 VLA-4 inhibitor compounds VCAM1, ICAM1, ITGA4 NPC1 2939/4885FPR3 268/4885FPR2 392/4885
US-20070054909-A1 VLA-4 inhibitor compounds VCAM1, ITGB4, ICAM1 NPC1 3300/4885FPR3 303/4885FPR2 414/4885
US-20040229858-A1 VLA-4 inhibitor compounds VCAM1, ICAM1, ITGB4 NPC1 2981/4885FPR3 294/4885FPR2 405/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.